Michael W. Traxlmayr
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michael W. Traxlmayr has a total of 231 co-authors. Here are the top co-authors by number of shared publications:
- Christian Obinger
Department of Chemistry, Institute of Biochemistry, University of Natural Resources and Life Sciences, Vienna, Austria
15 shared publications - Elisabeth Laurent
Institute of Molecular Biotechnology, Department of Biotechnology and Core Facility Biomolecular & Cellular Analysis, University of Natural Resources and Life Sciences (BOKU)
8 shared publications - Florian Rüker
University of Natural Resources and Life Sciences (BOKU)
8 shared publications Christoph Hasenhindl
Christian Doppler Laboratory for Antibody Engineering, BOKU - University of Natural Resources and Life Sciences, Muthgasse 18, 1190 Vienna, Austria; Department of Chemistry, Division of Biochemistry, BOKU - University of Natural Resources and Life Sciences, Muthgasse 18, 1190 Vienna, Austria
7 shared publicationsGerhard Stadlmayr
Christian Doppler Laboratory for Antibody Engineering at Department of Chemistry and Department of Biotechnology, BOKU – University of Natural Resources and Life Sciences, Vienna, Austria
7 shared publicationsCharlotte U. Zajc
CD Laboratory for Next Generation CAR T Cells, Vienna, Austria
6 shared publications
Latest Publications
- 5 July 2026
- Published by Springer Nature
- Vol. 3030, 227-251
Engineering and Adapting Disulfide-Containing Proteins to Enable Intracellular Functionality
Disulfide bonds are key structural components ensuring proper protein folding. Those bonds, however, do not form in the reducing intracellular environment, often resulting in misfolded, unstable proteins with subpar function. To enable intracellular functionality of such proteins, disulfide-free variants with restored stability and function should be engineered. Here, we present a method to substitute the cysteine residues with optimal amino acid combinations using site saturation mutagenesis and screening for improved disulfide-free variants using yeast surface display. We provide a detailed protocol to directly screen for thermal stability of proteins using conformationally specific ligands, and an alternative to harness the correlation between protein stability and expression levels in yeast. We also discuss different strategies for randomizing cysteine residues and approaches for handling proteins with multiple disulfide bonds.
- 5 July 2026
- Published by Springer Nature
- Vol. 3030, 227-251
Engineering and Adapting Disulfide-Containing Proteins to Enable Intracellular Functionality
Disulfide bonds are key structural components ensuring proper protein folding. Those bonds, however, do not form in the reducing intracellular environment, often resulting in misfolded, unstable proteins with subpar function. To enable intracellular functionality of such proteins, disulfide-free variants with restored stability and function should be engineered. Here, we present a method to substitute the cysteine residues with optimal amino acid combinations using site saturation mutagenesis and screening for improved disulfide-free variants using yeast surface display. We provide a detailed protocol to directly screen for thermal stability of proteins using conformationally specific ligands, and an alternative to harness the correlation between protein stability and expression levels in yeast. We also discuss different strategies for randomizing cysteine residues and approaches for handling proteins with multiple disulfide bonds.
- Open Access
- 10 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Balancing the efficacy and safety of chimeric antigen receptor T-cell therapy by affinity combination
Recent studies suggest that Chimeric Antigen Receptor (CAR) binding affinity to its ligand affects CAR-T-cell functionality. Affinity engineering towards lower binding strengths might mitigate therapeutic side effects arising from intense CAR-T-cell activation as well as tumor relapse due to antigen-escape or limited persistence of CAR-T cells during sustained activation via high-affinity receptors. Here we characterize a broad range of CARs with varying affinities to the same target epitope and leverage the insights we gain to design a combined high- and low-affinity CAR product. While CAR affinity impacts in vitro functionality minimally, it strongly correlates with tumor control in vivo. Low-affinity binders cause only mild cytokine release syndrome (CRS) in humanized mouse models at the expense of anti-tumour efficiency. In mixtures with low-affinity CARs, high-affinity CARs maintain strong functionality while showing reduced signs of exhaustion and monocyte-induced cytokine production, compared to high-affinity CAR-T cells alone. In long term in vitro and in vivo settings, low-affinity CAR-T cells dominate over time, proving more resilience to chronic antigen exposure. Overall, our findings demonstrate that affinity combination represents a promising strategy to generate more effective CAR-T-cell products with an improved therapeutic index, beyond affinity engineering alone.
- 10 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessBalancing the efficacy and safety of chimeric antigen receptor T-cell therapy by affinity combination
Recent studies suggest that Chimeric Antigen Receptor (CAR) binding affinity to its ligand affects CAR-T-cell functionality. Affinity engineering towards lower binding strengths might mitigate therapeutic side effects arising from intense CAR-T-cell activation as well as tumor relapse due to antigen-escape or limited persistence of CAR-T cells during sustained activation via high-affinity receptors. Here we characterize a broad range of CARs with varying affinities to the same target epitope and leverage the insights we gain to design a combined high- and low-affinity CAR product. While CAR affinity impacts in vitro functionality minimally, it strongly correlates with tumor control in vivo. Low-affinity binders cause only mild cytokine release syndrome (CRS) in humanized mouse models at the expense of anti-tumour efficiency. In mixtures with low-affinity CARs, high-affinity CARs maintain strong functionality while showing reduced signs of exhaustion and monocyte-induced cytokine production, compared to high-affinity CAR-T cells alone. In long term in vitro and in vivo settings, low-affinity CAR-T cells dominate over time, proving more resilience to chronic antigen exposure. Overall, our findings demonstrate that affinity combination represents a promising strategy to generate more effective CAR-T-cell products with an improved therapeutic index, beyond affinity engineering alone.
- Open Access
Intrinsically disordered insert from SH2D2A rewires CD19 CAR signaling via Tyr290
Chimeric antigen receptor (CAR) T cells have transformed cancer immunotherapy, yet their truncated or suboptimal intracellular signaling can limit therapeutic efficacy. To enhance proximal signaling of a CD19-targeted CAR, we systematically inserted short Lck-recruiting motifs derived from Lck-adaptor proteins into the CAR intracellular tail. Six candidate sequences from four adaptor molecules (SH2D2A, SKAP1, LAT, LIME), with a sequence from CD3ε, known to affect CAR functionality, as a positive control, were tested for expression and functional impact. Three CAR constructs (containing SH2D2A, LAT and LIME1 sequences respectively) displayed reduced surface expression, but only SH2D2A elicited a pronounced rewiring of CAR T cell phenotype following co-culture with CD19 + tumor lines. SH2D2A CAR T cells showed increased CD27 and CD56 expression and reduced expression of effector-associated mediators including granzyme B, IL-2, TNFα, and IFNγ. Through systematic mutagenesis and comparative phenotyping of SH2D2A CAR variants, we identified SH2D2A tyrosine 290 (Tyr290) as the critical residue mediating both the altered signaling phenotype and the low surface expression. Additionally, mutation of Tyr254 in the LIME1 CAR restored surface expression in Jurkat T cells, indicating insert- and context-dependent effects on receptor surface expression. Collectively, these results demonstrate that short, intrinsically disordered adaptor-derived sequences — and single tyrosine residues within them — can profoundly reprogram CAR signaling and expression.
Open AccessIntrinsically disordered insert from SH2D2A rewires CD19 CAR signaling via Tyr290
Chimeric antigen receptor (CAR) T cells have transformed cancer immunotherapy, yet their truncated or suboptimal intracellular signaling can limit therapeutic efficacy. To enhance proximal signaling of a CD19-targeted CAR, we systematically inserted short Lck-recruiting motifs derived from Lck-adaptor proteins into the CAR intracellular tail. Six candidate sequences from four adaptor molecules (SH2D2A, SKAP1, LAT, LIME), with a sequence from CD3ε, known to affect CAR functionality, as a positive control, were tested for expression and functional impact. Three CAR constructs (containing SH2D2A, LAT and LIME1 sequences respectively) displayed reduced surface expression, but only SH2D2A elicited a pronounced rewiring of CAR T cell phenotype following co-culture with CD19 + tumor lines. SH2D2A CAR T cells showed increased CD27 and CD56 expression and reduced expression of effector-associated mediators including granzyme B, IL-2, TNFα, and IFNγ. Through systematic mutagenesis and comparative phenotyping of SH2D2A CAR variants, we identified SH2D2A tyrosine 290 (Tyr290) as the critical residue mediating both the altered signaling phenotype and the low surface expression. Additionally, mutation of Tyr254 in the LIME1 CAR restored surface expression in Jurkat T cells, indicating insert- and context-dependent effects on receptor surface expression. Collectively, these results demonstrate that short, intrinsically disordered adaptor-derived sequences — and single tyrosine residues within them — can profoundly reprogram CAR signaling and expression.
- Open Access
- 18 December 2025
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 800, 153165
Specific detection of EGF-EGFR complexes on the cell surface and their dependency on EGFR-directed TKI treatment
- 18 December 2025
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 800, 153165
Open AccessSpecific detection of EGF-EGFR complexes on the cell surface and their dependency on EGFR-directed TKI treatment
- 17 October 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (112) , eado3825
Protein palmitoylation and sphingolipid metabolism control regulated exocytosis in cytotoxic lymphocytes
Regulated exocytosis controls key cellular functions ranging from neurotransmitter release to the secretion of immune mediators, and its disruption is associated with numerous pathologies. The cytotoxic activity of lymphocytes is particularly dependent on regulated and polarized lytic granule delivery toward infected or malignant cells. Although genetic and mechanistic studies have identified factors regulating exocytosis in cytotoxic lymphocytes, a systematic mapping of the relevant factors and their relationships is lacking. Through a genome-scale CRISPR knockout screen in a human natural killer cell line, we characterized a complex genetic network regulating cytotoxic granule exocytosis, with lipid metabolism and protein lipidation among the most prominent pathways. By combining global protein palmitoylation and lipidomic studies, we found that ZDHHC17 drives palmitoylation of the core SNARE complex protein SNAP23 to target cytotoxic granules to GM1-rich lipid rafts whose assembly is controlled by serine palmitoyltransferase. In summary, our study identifies previously unrecognized factors essential for cytotoxic function in human lymphocytes and uncovers how lipid metabolism and protein palmitoylation are involved in the process of regulated exocytosis.
- 17 October 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (112) , eado3825
Protein palmitoylation and sphingolipid metabolism control regulated exocytosis in cytotoxic lymphocytes
Regulated exocytosis controls key cellular functions ranging from neurotransmitter release to the secretion of immune mediators, and its disruption is associated with numerous pathologies. The cytotoxic activity of lymphocytes is particularly dependent on regulated and polarized lytic granule delivery toward infected or malignant cells. Although genetic and mechanistic studies have identified factors regulating exocytosis in cytotoxic lymphocytes, a systematic mapping of the relevant factors and their relationships is lacking. Through a genome-scale CRISPR knockout screen in a human natural killer cell line, we characterized a complex genetic network regulating cytotoxic granule exocytosis, with lipid metabolism and protein lipidation among the most prominent pathways. By combining global protein palmitoylation and lipidomic studies, we found that ZDHHC17 drives palmitoylation of the core SNARE complex protein SNAP23 to target cytotoxic granules to GM1-rich lipid rafts whose assembly is controlled by serine palmitoyltransferase. In summary, our study identifies previously unrecognized factors essential for cytotoxic function in human lymphocytes and uncovers how lipid metabolism and protein palmitoylation are involved in the process of regulated exocytosis.
- Open Access
Caffeine-regulated molecular switches for functional control of CAR T cells in vivo
The limited controllability of CAR T cells in patients represents a key challenge of this highly potent immunotherapy. A molecular ON-switch, which can be regulated with a non-toxic and readily available small molecule drug, would represent a major advance towards controllable CAR T therapeutics. For that purpose, we engineered caffeine-responsive heterodimeric ON-switches (CaffSwitches) and demonstrate their high caffeine-dependency and virtually absent leakiness. When incorporating these CaffSwitches into CARs, the resulting CaffCARs were efficiently activated by caffeine concentrations achieved in human plasma after drinking one cup of coffee. Moreover, CaffCAR T cells also showed efficient tumor clearance in an in vivo mouse model, which was completely abolished in the absence of caffeine. This tight control was even observed with c-Jun overexpressing CaffCAR T cells, despite their massive expansion. Together, we anticipate that these novel CaffSwitches will be valuable tools for the development of safe and efficient next generation CAR T cells.
Open AccessCaffeine-regulated molecular switches for functional control of CAR T cells in vivo
The limited controllability of CAR T cells in patients represents a key challenge of this highly potent immunotherapy. A molecular ON-switch, which can be regulated with a non-toxic and readily available small molecule drug, would represent a major advance towards controllable CAR T therapeutics. For that purpose, we engineered caffeine-responsive heterodimeric ON-switches (CaffSwitches) and demonstrate their high caffeine-dependency and virtually absent leakiness. When incorporating these CaffSwitches into CARs, the resulting CaffCARs were efficiently activated by caffeine concentrations achieved in human plasma after drinking one cup of coffee. Moreover, CaffCAR T cells also showed efficient tumor clearance in an in vivo mouse model, which was completely abolished in the absence of caffeine. This tight control was even observed with c-Jun overexpressing CaffCAR T cells, despite their massive expansion. Together, we anticipate that these novel CaffSwitches will be valuable tools for the development of safe and efficient next generation CAR T cells.
- 30 November 2024
- Published by MyJove Corporation
- p. e66994
JoVE Video Dataset
Protein engineering enables the improvement of existing functions of a given protein or the generation of novel functions. One of the most widely used and versatile tools in the protein engineering field is yeast surface display, where a pool of randomized proteins is expressed on the surface of yeast. The linkage of phenotype (e.g., binding of the yeast-displayed protein to the antigen of interest) and genotype (the plasmid encoding for the protein variant) enables selection of this library for desired properties and subsequent sequencing of enriched variants. By combining magnetic bead selection with flow cytometric sorting, protein variants with enhanced binding to a target antigen can be selected and enriched. Notably, in addition to affinity maturation, binding to a target can also be achieved without any initial binding affinity. Here, we provide a step-by-step protocol that covers all essential parts of a yeast surface display selection campaign and gives examples of typical yeast surface display results. We demonstrate that yeast surface display is a broadly applicable and robust method that can be established in any molecular biology laboratory with access to flow cytometry.
- 30 November 2024
- Published by MyJove Corporation
- p. e66994
JoVE Video Dataset
Protein engineering enables the improvement of existing functions of a given protein or the generation of novel functions. One of the most widely used and versatile tools in the protein engineering field is yeast surface display, where a pool of randomized proteins is expressed on the surface of yeast. The linkage of phenotype (e.g., binding of the yeast-displayed protein to the antigen of interest) and genotype (the plasmid encoding for the protein variant) enables selection of this library for desired properties and subsequent sequencing of enriched variants. By combining magnetic bead selection with flow cytometric sorting, protein variants with enhanced binding to a target antigen can be selected and enriched. Notably, in addition to affinity maturation, binding to a target can also be achieved without any initial binding affinity. Here, we provide a step-by-step protocol that covers all essential parts of a yeast surface display selection campaign and gives examples of typical yeast surface display results. We demonstrate that yeast surface display is a broadly applicable and robust method that can be established in any molecular biology laboratory with access to flow cytometry.
- 29 November 2024
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 213,p. e66994
Protein Engineering by Yeast Surface Display
Protein engineering enables the improvement of existing functions of a given protein or the generation of novel functions. One of the most widely used and versatile tools in the protein engineering field is yeast surface display, where a pool of randomized proteins is expressed on the surface of yeast. The linkage of phenotype (e.g., binding of the yeast-displayed protein to the antigen of interest) and genotype (the plasmid encoding for the protein variant) enables selection of this library for desired properties and subsequent sequencing of enriched variants. By combining magnetic bead selection with flow cytometric sorting, protein variants with enhanced binding to a target antigen can be selected and enriched. Notably, in addition to affinity maturation, binding to a target can also be achieved without any initial binding affinity. Here, we provide a step-by-step protocol that covers all essential parts of a yeast surface display selection campaign and gives examples of typical yeast surface display results. We demonstrate that yeast surface display is a broadly applicable and robust method that can be established in any molecular biology laboratory with access to flow cytometry.
- 29 November 2024
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 213,p. e66994
Protein Engineering by Yeast Surface Display
Protein engineering enables the improvement of existing functions of a given protein or the generation of novel functions. One of the most widely used and versatile tools in the protein engineering field is yeast surface display, where a pool of randomized proteins is expressed on the surface of yeast. The linkage of phenotype (e.g., binding of the yeast-displayed protein to the antigen of interest) and genotype (the plasmid encoding for the protein variant) enables selection of this library for desired properties and subsequent sequencing of enriched variants. By combining magnetic bead selection with flow cytometric sorting, protein variants with enhanced binding to a target antigen can be selected and enriched. Notably, in addition to affinity maturation, binding to a target can also be achieved without any initial binding affinity. Here, we provide a step-by-step protocol that covers all essential parts of a yeast surface display selection campaign and gives examples of typical yeast surface display results. We demonstrate that yeast surface display is a broadly applicable and robust method that can be established in any molecular biology laboratory with access to flow cytometry.
- Open Access
- 24 September 2024
- Published by Elsevier in STAR Protocols
- Vol. 5 (4) , 103339
Protocol for engineering binding domains to recognize ligand-bound receptors by using yeast surface display
- 24 September 2024
- Published by Elsevier in STAR Protocols
- Vol. 5 (4) , 103339
Open AccessProtocol for engineering binding domains to recognize ligand-bound receptors by using yeast surface display
- Open Access
- 2 June 2024
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 24 (6) , 425-432
Small molecule-regulated switches to provide functional control of CAR T cells within the patient
1. T cells genetically engineered to express chimeric antigen receptors (CAR T cells) represent a highly potent type of cancer immunotherapy, especially for the treatment of hematologic malignancie...
- 2 June 2024
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 24 (6) , 425-432
Open AccessSmall molecule-regulated switches to provide functional control of CAR T cells within the patient
1. T cells genetically engineered to express chimeric antigen receptors (CAR T cells) represent a highly potent type of cancer immunotherapy, especially for the treatment of hematologic malignancie...